AR048050A1 - Formas de administracion masticables, no comprimidas, dosificadas individualmente - Google Patents

Formas de administracion masticables, no comprimidas, dosificadas individualmente

Info

Publication number
AR048050A1
AR048050A1 ARP040104105A ARP040104105A AR048050A1 AR 048050 A1 AR048050 A1 AR 048050A1 AR P040104105 A ARP040104105 A AR P040104105A AR P040104105 A ARP040104105 A AR P040104105A AR 048050 A1 AR048050 A1 AR 048050A1
Authority
AR
Argentina
Prior art keywords
individually dosed
compressed
masticable
methods
administration forms
Prior art date
Application number
ARP040104105A
Other languages
English (en)
Spanish (es)
Inventor
Vidal Jose Luis Fabregas
Carbonell Antoni Masso
Gonzalez Nuria Garcia
Coli Pere Guiro
Original Assignee
Almirall Prodesfarma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34610359&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR048050(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Almirall Prodesfarma Sa filed Critical Almirall Prodesfarma Sa
Publication of AR048050A1 publication Critical patent/AR048050A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP040104105A 2003-11-10 2004-11-08 Formas de administracion masticables, no comprimidas, dosificadas individualmente AR048050A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200302612A ES2235626B1 (es) 2003-11-10 2003-11-10 Formas de administracion masticables, no comprimidas dosificadas individualmente.

Publications (1)

Publication Number Publication Date
AR048050A1 true AR048050A1 (es) 2006-03-29

Family

ID=34610359

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040104105A AR048050A1 (es) 2003-11-10 2004-11-08 Formas de administracion masticables, no comprimidas, dosificadas individualmente

Country Status (25)

Country Link
US (1) US20070134318A1 (enExample)
EP (1) EP1682097B1 (enExample)
JP (1) JP4879021B2 (enExample)
KR (1) KR20060116821A (enExample)
CN (1) CN1878542A (enExample)
AR (1) AR048050A1 (enExample)
AT (1) ATE492270T1 (enExample)
AU (1) AU2004290517B2 (enExample)
BR (1) BRPI0416215A (enExample)
CA (1) CA2548615A1 (enExample)
CO (1) CO5690531A2 (enExample)
DE (1) DE602004030706D1 (enExample)
EC (1) ECSP066553A (enExample)
ES (2) ES2235626B1 (enExample)
IL (1) IL175285A (enExample)
MY (1) MY143793A (enExample)
NO (1) NO20062723L (enExample)
NZ (1) NZ546375A (enExample)
PE (1) PE20050488A1 (enExample)
RU (1) RU2369379C2 (enExample)
TW (1) TW200526266A (enExample)
UA (1) UA90253C2 (enExample)
UY (1) UY28586A1 (enExample)
WO (2) WO2005048975A1 (enExample)
ZA (1) ZA200602416B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050089559A1 (en) 2003-10-23 2005-04-28 Istvan Szelenyi Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
US7960436B2 (en) 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
US8993593B2 (en) 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
ES2420960T3 (es) 2006-08-23 2013-08-28 Valeant Pharmaceuticals International Derivados de 4-(N-azacicloalquil)anilidas como moduladores de los canales de potasio
AU2007325629A1 (en) 2006-11-28 2008-06-05 Valeant Pharmaceuticals International 1,4 diamino bicyclic retigabine analogues as potassium channel modulators
US8367684B2 (en) 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
WO2009002084A2 (en) * 2007-06-27 2008-12-31 Hanmi Pharm. Co., Ltd. Method for preparing rapidly disintegrating formulation for oral administration and apparatus for preparing and packing the same
IL187159A0 (en) 2007-07-03 2009-02-11 Gur Megiddo Use of metadoxine in relief of alcohol intoxication
US7786146B2 (en) 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
EP2323735A1 (en) 2008-07-29 2011-05-25 Alcobra Ltd. Substituted pyridoxine-lactam carboxylate salts
EP2238976B1 (en) * 2009-04-03 2012-06-27 Hexal AG Oral films comprising 7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-3,4-dihydro- 1H-quinolin-2-one base or salts or hydrates thereof
CA2766107A1 (en) 2009-06-25 2010-12-29 Alcobra Ltd. A method for the treatment, alleviation of symptoms of, relieving, improving and preventing a cognitive disease, disorder or condition
EA021368B1 (ru) * 2011-06-21 2015-06-30 Общество С Ограниченной Ответственностью "Консорциум-Пик" Препарат кардиопротекторного действия
CN105911057B (zh) * 2016-06-22 2018-10-19 扬州一洋制药有限公司 一种铝镁加混悬液的质量控制方法
TWI886158B (zh) 2019-10-10 2025-06-11 加拿大商再諾製藥公司 選擇性鉀通道調節劑之固態晶型
PH12022551110A1 (en) 2019-11-08 2024-02-26 Xenon Pharmaceuticals Inc Methods of treating depressive disorders
JP2024508660A (ja) 2021-02-09 2024-02-28 ゼノン・ファーマシューティカルズ・インコーポレイテッド 快感消失の治療に使用するための電位依存性カリウムチャネル開口薬
CN113425694A (zh) * 2021-07-02 2021-09-24 杭州蚕宝生物技术有限公司 一种石斛生物碱口腔崩解片剂及其制备方法
US12053484B2 (en) 2021-10-29 2024-08-06 Medicated Chews, Llc Simethicone chewable composition

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5645411A (en) * 1979-09-20 1981-04-25 Taiho Yakuhin Kogyo Kk Poultice
FR2515035A1 (fr) * 1981-10-26 1983-04-29 Rhone Poulenc Sante Nouvelle forme galenique solide pour administration par voie orale et son procede de fabrication
EP0409432A3 (en) * 1989-07-20 1991-12-11 Warner-Lambert Company Confectionery delivery system
US5433951A (en) * 1993-10-13 1995-07-18 Bristol-Myers Squibb Company Sustained release formulation containing captopril and method
JPH08319232A (ja) * 1995-03-22 1996-12-03 Takeda Chem Ind Ltd 粉粒状組成物
JPH0912463A (ja) * 1995-06-23 1997-01-14 Fujisawa Pharmaceut Co Ltd 口中咀嚼用製剤
US20030216303A1 (en) * 1998-03-06 2003-11-20 Michael Ambuhl Emulsion preconcentrates containing cyclosporin or a macrolide
US6171615B1 (en) * 1998-07-06 2001-01-09 Gattefoss{acute over (e)} Sustained release theophylline formulations, excipient systems and methods of production
US6060078A (en) * 1998-09-28 2000-05-09 Sae Han Pharm Co., Ltd. Chewable tablet and process for preparation thereof
US6652880B1 (en) * 1999-04-01 2003-11-25 R.P. Scherer Technologies, Inc. Oral pharmaceutical compositions containing long-chain triglycerides and liphophilic surfactants
EP2298284A3 (en) * 2001-02-14 2013-12-18 GW Pharma Limited Mucoadhesive pharmaceutical formulations
US6692771B2 (en) * 2001-02-23 2004-02-17 Cima Labs Inc. Emulsions as solid dosage forms for oral administration
RU2197094C1 (ru) * 2001-12-26 2003-01-27 Ставрулов Игорь Анатольевич Жевательная резинка

Also Published As

Publication number Publication date
CO5690531A2 (es) 2006-10-31
ATE492270T1 (de) 2011-01-15
AU2004290517A1 (en) 2005-06-02
ECSP066553A (es) 2006-12-20
WO2005048974A2 (en) 2005-06-02
AU2004290517B2 (en) 2010-05-27
EP1682097A2 (en) 2006-07-26
WO2005048974A3 (en) 2006-02-23
ZA200602416B (en) 2009-06-24
IL175285A (en) 2011-04-28
NZ546375A (en) 2009-11-27
EP1682097B1 (en) 2010-12-22
ES2235626A1 (es) 2005-07-01
CN1878542A (zh) 2006-12-13
PE20050488A1 (es) 2005-08-24
ES2358332T3 (es) 2011-05-09
JP4879021B2 (ja) 2012-02-15
MY143793A (en) 2011-07-15
TW200526266A (en) 2005-08-16
BRPI0416215A (pt) 2006-12-26
US20070134318A1 (en) 2007-06-14
UY28586A1 (es) 2005-05-31
NO20062723L (no) 2006-06-12
IL175285A0 (en) 2006-09-05
UA90253C2 (ru) 2010-04-26
RU2006120087A (ru) 2007-12-27
RU2369379C2 (ru) 2009-10-10
KR20060116821A (ko) 2006-11-15
DE602004030706D1 (de) 2011-02-03
WO2005048975A1 (en) 2005-06-02
CA2548615A1 (en) 2005-06-02
ES2235626B1 (es) 2006-11-01
JP2007510690A (ja) 2007-04-26

Similar Documents

Publication Publication Date Title
AR048050A1 (es) Formas de administracion masticables, no comprimidas, dosificadas individualmente
ES2167061T3 (es) Formas de dosificacion para mejorar la disfuncion erectil en pacientes de sexo masculino.
CL2008002407A1 (es) Forma de dosificacion oral que comprende al menos un agente activo de nicotina, al menos un material bioadhesivo capaz de formar un enlace de hidrogeno con el agente activo de nicotina, y al menos un agente de impacto sensorial que se libere rapidamente; y su uso para proporcionar alivio rapido de las ansias de nicotina (div. sol. 1825-04).
AR049083A1 (es) Proceso para la preparacion de una forma de dosificacion solida a prueba de abuso
HRP20060147B1 (hr) Terapijski sustav s kontroliranim otpuštanjem za nazalnu primjenu
CR6656A (es) Forma de dosificacion de farmacos accionada por un hidrogel
AR058175A1 (es) Composiciones farmaceuticas solidas que contienen pregabalina
AR046510A1 (es) Composicion de un antagonista de vegf y un agente anti-proliferativo
AR044131A1 (es) Peliculas consumibles oralmente de disolucion rapida que contienen un almidon modificado para la mejora de la resistencia al calor y a la humedad
PA8601401A1 (es) Peliculas consumibles por via oral que se disuelven rapidamiente, que contienen un edulcorante
AR071850A1 (es) Gomas de mascar en forma de tableta
AR109263A2 (es) Composición que comprende moxidectina
AR029562A1 (es) Forma de administracion desintegrable ra pidamente para la liberacion de principios activos en la cavidad bucal o en otras cavidades corporales, proceso de fabricacion y usos
AR052057A1 (es) Composiciones orales que contienen extractos de rosmarinus y metodos ralacionados
PA8559501A1 (es) Formulaciones farmaceuticas de 5,7,14-triazatetraciclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaeno
ECSP034826A (es) Método para fabricar una composición farmacéutica de dosis baja
CO6640264A2 (es) Combinación de gránulos cargados activos con activos adicionales
SV2003001098A (es) Formulacion farmaceutica de sabor enmascarado y procedimiento para su preparacion
CL2004001843A1 (es) Combinacion de (a) al menos un derivado 2,5-dihidrobencenosulfonico, como el dobeilato calcico, etamsilato y persilato, y (b) al menos un modulador de los canales de potasio, composicion farmaceutica que la contiene y uso como medicamento en profilax
PE20050443A1 (es) Formulaciones farmaceuticas transdermicas
CR9112A (es) Formas de dosificacion oral solidas que contienen una dosis baja de estradiol
UY23355A1 (es) Formulacion para verter destinada a la aplicacion de antihelminticos
CL2004000884A1 (es) Composicion farmaceutica en forma de hidrogel que contiene un diester de acido carbonico, un alquilalcohol c2-c4, por lo menos una sustancia activa y una matriz de polimero; uso en el tratamiento de carencias esteroidales.
CL2004000767A1 (es) Unidad de dosificacion oral que comprende un agente antagonista de bombas de protones y excipientes de caracter basico; procedimiento para su preparacion, utiles para tratar enfermedades causadas por una secrecion aumentada de acidos gastricos.
AR043019A1 (es) Formas de dosificacion solida transmucosal oral libres de azucar y sus usos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal